On April 27, 2026, NervGen Pharma Corp. appointed Dr. Keith Vendola as the Chief Financial Officer, with an annual salary of $515,000 and stock options for 812,002 shares at $3.92 each. The appointment follows a shareholder meeting on April 23, 2026, where key amendments and plans were approved.